Switch theme
Sign up to access all valuation multiples
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
1998
n/a
LTM Revenue $231M
LTM EBITDA $79.1M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aurisco Pharmaceutical has a last 12-month revenue (LTM) of $231M and a last 12-month EBITDA of $79.1M.
In the most recent fiscal year, Aurisco Pharmaceutical achieved revenue of $206M and an EBITDA of $71.4M.
Aurisco Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aurisco Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $231M | XXX | $206M | XXX | XXX | XXX |
| Gross Profit | $135M | XXX | $121M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $79.1M | XXX | $71.4M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 35% | XXX | XXX | XXX |
| EBIT | $67.4M | XXX | $57.5M | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $58.2M | XXX | $49.5M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $22.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Aurisco Pharmaceutical's stock price is CNY 22 (or $3).
Aurisco Pharmaceutical has current market cap of CNY 8.8B (or $1.2B), and EV of CNY 8.8B (or $1.2B).
See Aurisco Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.2B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Aurisco Pharmaceutical has market cap of $1.2B and EV of $1.2B.
Aurisco Pharmaceutical's trades at 6.0x EV/Revenue multiple, and 17.3x EV/EBITDA.
Equity research analysts estimate Aurisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aurisco Pharmaceutical has a P/E ratio of 21.2x.
See valuation multiples for Aurisco Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | 15.6x | XXX | 17.3x | XXX | XXX | XXX |
| EV/EBIT | 18.3x | XXX | 21.4x | XXX | XXX | XXX |
| EV/Gross Profit | 9.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.2x | XXX | 24.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -42.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAurisco Pharmaceutical's last 12 month revenue growth is 20%
Aurisco Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Aurisco Pharmaceutical's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aurisco Pharmaceutical's rule of X is 84% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aurisco Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | 53% | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 84% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aurisco Pharmaceutical acquired XXX companies to date.
Last acquisition by Aurisco Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Aurisco Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aurisco Pharmaceutical founded? | Aurisco Pharmaceutical was founded in 1998. |
| Where is Aurisco Pharmaceutical headquartered? | Aurisco Pharmaceutical is headquartered in China. |
| Is Aurisco Pharmaceutical publicy listed? | Yes, Aurisco Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Aurisco Pharmaceutical? | Aurisco Pharmaceutical trades under 605116 ticker. |
| When did Aurisco Pharmaceutical go public? | Aurisco Pharmaceutical went public in 2020. |
| Who are competitors of Aurisco Pharmaceutical? | Similar companies to Aurisco Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's current market cap is $1.2B |
| What is the current revenue of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's last 12 months revenue is $231M. |
| What is the current revenue growth of Aurisco Pharmaceutical? | Aurisco Pharmaceutical revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Aurisco Pharmaceutical? | Current revenue multiple of Aurisco Pharmaceutical is 5.3x. |
| Is Aurisco Pharmaceutical profitable? | Yes, Aurisco Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's last 12 months EBITDA is $79.1M. |
| What is Aurisco Pharmaceutical's EBITDA margin? | Aurisco Pharmaceutical's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Aurisco Pharmaceutical? | Current EBITDA multiple of Aurisco Pharmaceutical is 15.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
